Skip to content

US · MXCT · BIOTECHNOLOGY

MaxCyte, Inc. (MXCT) intrinsic value and stock valuation

$1.37as of 2026-11-21 · Mkt cap 126.4M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MaxCyte, Inc. DCF and intrinsic value

InvestorsCraft values MXCT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MXCT’s statements →

MaxCyte, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Rockville, MD 20850 maxcyte.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$33M+4.8% 5y CAGRd
20122025
Net income
-$-44.63M
20122025
Free cash flow
-$-36.18M
20122025
Total equity
$171.5M+38.8% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$33M$38.6M$41.3M$44.3M$33.9M
Operating income-$-45.28M-$-51.2M-$-48.3M-$-27.36M-$-18.19M
Net income-$-44.63M-$-41.05M-$-37.92M-$-23.57M-$-19.08M
EPSd-$-419.34K-$-391.51K-$-367.19K-$-231.76K-$-210.55K
Operating cash flow-$-34.41M-$-27.61M-$-21.69M-$-14.78M-$-10.68M
Capital expenditure-$-1.77M-$-1.65M-$-3.7M-$-18.48M-$-3.83M
Free cash flow-$-36.18M-$-29.26M-$-25.39M-$-33.26M-$-14.51M
Total assets$202.5M$239.5M$268.3M$286.7M$284.1M
Total debt$17.9M$18M$18.7M$16.1M$5.68M
Net debt-$-2.12M-$-9.85M-$-27.76M$5.03M-$-42.1M
Total equity$171.5M$206.3M$232.2M$254M$262.9M
Cash and short-term investments$103M$154.5M$168.3M$227.3M$255M
Income statement
20252024202320222021
Revenue$33M$38.6M$41.3M$44.3M$33.9M
Cost of revenue$6.22M$7.1M$4.74M$5.1M$3.65M
Gross profit$26.8M$31.5M$36.6M$39.2M$30.3M
Research and development expenses$20.8M$22.2M$23.8M$19.5M$15.4M
Selling, general and administrative expenses$47M$56.4M$57M$44.5M$31.7M
Other expenses$4.23M$4.14M$3.98M$2.53M$1.35M
Operating expenses$72.1M$82.7M$84.8M$66.5M$48.4M
Cost and expenses$78.3M$89.8M$89.6M$71.6M$52.1M
Interest income$7.27M$10.1M$10.4M$3.92M$150K
Interest expense$0.00$0.00$0.00$130K$1.04M
Depreciation and amortization$5.14M$4.79M$4.17M$2.7M$1.42M
Ebitda-$-39.49M-$-36.27M-$-33.75M-$-20.75M-$-16.61M
Operating income-$-45.28M-$-51.2M-$-48.3M-$-27.36M-$-18.19M
Total other income/expenses, net$660K$10.1M$10.4M$3.79M-$-890K
Income before tax-$-44.63M-$-41.05M-$-37.92M-$-23.57M-$-19.08M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-44.63M-$-41.05M-$-37.92M-$-23.57M-$-19.08M
Weighted average shares outstanding$106.4M$104.9M$103.3M$101.7M$90.6M
Weighted average diluted shares outstanding$106.4M$104.9M$103.3M$101.7M$90.6M
Balance sheet
20252024202320222021
Cash and short-term investments$103M$154.5M$168.3M$227.3M$255M
Net receivables$3.5M$4.68M$5.78M$11.2M$6.88M
Inventory$7.55M$8.91M$12.2M$8.58M$5.2M
Total current assets$118.4M$171.7M$190.2M$252.3M$270.4M
Property, plant and equipment, net$28.5M$30.5M$34.8M$33.6M$13.4M
Goodwill and intangible assets$650K$0.00$0.00$0.00$0.00
Long-term investments$52.6M$35.8M$42.9M$0.00$0.00
Total non-current assets$84.1M$67.8M$78.1M$34.4M$13.7M
Total assets$202.5M$239.5M$268.3M$286.7M$284.1M
Accounts payable$1.4M$1.36M$740K$290K$1.82M
Short-term debt$1.46M$860K$770K$160K$530K
Deferred revenue$3.6M$5.25M$5.07M$0.00$6.75M
Total current liabilities$14.3M$15.8M$17.9M$15.4M$15.6M
Long-term debt$16.5M$17.2M$18M$15.9M$5.15M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$16.8M$17.4M$18.3M$17.3M$5.61M
Capital lease obligations$16.5M$17.2M$18.7M$16.1M$5.68M
Total liabilities$31M$33.2M$36.1M$32.7M$21.2M
Common stock$1.07M$1.06M$1.04M$1.02M$1.01M
Retained earnings-$-261.48M-$-216.85M-$-175.8M-$-137.88M-$-114.3M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$0.00$0.00
Total equity$171.5M$206.3M$232.2M$254M$262.9M
Total investments$135.6M$162.4M$164.7M$216.3M$207.3M
Total debt$17.9M$18M$18.7M$16.1M$5.68M
Net debt-$-2.12M-$-9.85M-$-27.76M$5.03M-$-42.1M
Cash flow statement
20252024202320222021
Net income-$-44.63M-$-41.05M-$-37.92M-$-23.57M-$-19.08M
Depreciation and amortization$5.14M$4.32M$4.57M$2.7M$1.42M
Stock-based compensation$9.21M$0.00$14M$0.00$7.96M
Change in working capital-$-6.12M-$-750K$3.82M-$-3.21M-$-1.64M
Accounts receivable$1.15M$1.23M$7.14M-$-6.69M-$-1.71M
Inventory$570K$1.36M-$-4.53M-$-3.49M-$-1.41M
Accounts payable-$-3.72M-$-1.88M$3.25M-$-150K$2.09M
Net cash provided by operating activities-$-34.41M-$-27.61M-$-21.69M-$-14.78M-$-10.68M
Investments in property, plant and equipment-$-1.77M-$-1.65M-$-3.7M-$-18.48M-$-3.83M
Acquisitions, net-$-1.77M$0.00$0.00$0.00$0.00
Net cash used for investing activities$25.9M$6.93M$55M-$-24.82M-$-195.01M
Common stock issued$660K$2.06M$270K$2.89M$236.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$660K$2.06M$2.14M$2.89M$234.7M
Net change in cash-$-7.82M-$-18.62M$35.4M-$-36.72M$29M
Cash at end of period$20.1M$27.9M$46.5M$11.1M$47.8M
Operating cash flow-$-34.41M-$-27.61M-$-21.69M-$-14.78M-$-10.68M
Capital expenditure-$-1.77M-$-1.65M-$-3.7M-$-18.48M-$-3.83M
Free cash flow-$-36.18M-$-29.26M-$-25.39M-$-33.26M-$-14.51M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MaxCyte, Inc.

        MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

        CEO
        Maher Masoud
        Employees
        91
        Beta
        1.49

        Explore

        Frequently asked questions

        What is the intrinsic value of MaxCyte, Inc. (MXCT)?

        MaxCyte, Inc. (MXCT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MXCT undervalued?

        MXCT trades at a price of $1.37 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.